Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 17/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11539322 | 0.88 | RAB9A (0.58) | NPC1RAB9AP2RX7PTGDR2 | |
| SCHEMBL1195590 | 0.86 | NPC1 (0.73) | NPC1RAB9AP2RX7PTGDR2 | |
| SCHEMBL11264646 | 0.85 | NPC1 (0.56) | NPC1RAB9AP2RX7PTGDR2 | |
| SCHEMBL8512906 | 0.84 | NPC1 (0.62) | NPC1RAB9AP2RX7PTGDR2 | |
| SCHEMBL11254639 | 0.83 | PDE4D (0.59) | NPC1RAB9AP2RX7PTGDR2 | |
| SCHEMBL21711442 | 0.82 | SLC34A1 (0.73) | — | |
| SCHEMBL8511017 | 0.79 | PTGDR2 (0.60) | P2RX7PTGDR2 | |
| SCHEMBL28734538 | 0.79 | PTGDR2 (0.50) | NPC1RAB9AP2RX7PTGDR2 | |
| SCHEMBL28734553 | 0.79 | NPC1 (0.49) | NPC1RAB9AP2RX7ARPTGDR2 | |
| SCHEMBL3828501 | 0.77 | NPC1 (0.57) | NPC1RAB9AP2RX7PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155685-B1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-2155685-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138876-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX1 | NPC1 1266/4885RAB9A 2601/4885P2RX7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.